

Xalkori® (crizotinib) – New indication

- On January 14, 2021, <u>Pfizer announced</u> the FDA approval of <u>Xalkori (crizotinib)</u>, for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.
 - The safety and efficacy of Xalkori have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
- Xalkori is also approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK or ROS1-positive as detected by an FDA-approved test.
- The approval of Xalkori for the new indication was based on a single arm, open-label study in 26 patients 1 to ≤ 21 years of age with relapsed or refractory, systemic ALK-positive ALCL. Patients received Xalkori until disease progression or unacceptable toxicity. Efficacy was based on objective response rate (ORR) and duration of response (DOR).
 - The ORR was 88% (95% CI: 71, 96). Among the 23 patients who achieved a response, 22% maintained a response at 12 months.
- The most common adverse reactions (≥ 35%) with Xalkori use in patients with ALCL were diarrhea, vomiting, nausea, vision disorder, headache, musculoskeletal pain, stomatitis, fatigue, decreased appetite, pyrexia, abdominal pain, cough, and pruritus. Grade 3 to 4 laboratory abnormalities (≥ 15%) were neutropenia, lymphopenia, and thrombocytopenia.
- The recommended dose of Xalkori for the treatment of ALCL is 280 mg/m² orally twice daily until disease progression or unacceptable toxicity. The recommended dosage is based on body surface area (BSA) and provided in the table below.

BSA	Recommended Xalkori dosage
0.60 - 0.80 m ²	200 mg orally twice daily
0.81 - 1.16 m ²	250 mg orally twice daily
1.17 – 1.51 m ²	400 mg orally twice daily
1.52 – 1.69 m ²	450 mg orally twice daily
1.70 m ² or greater	500 mg orally twice daily

- The recommended dosage for patients with a BSA less than 0.60 m² has not been established.
- Refer to the Xalkori drug label for dosing in NSCLC.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.